CareDx, Inc. (CDNA): Price and Financial Metrics
CDNA Price/Volume Stats
| Current price | $7.00 | 52-week high | $20.71 |
| Prev. close | $7.04 | 52-week low | $6.22 |
| Day low | $6.87 | Volume | 673,900 |
| Day high | $7.28 | Avg. volume | 1,029,142 |
| 50-day MA | $9.11 | Dividend yield | N/A |
| 200-day MA | $10.22 | Market Cap | 379.18M |
CDNA Stock Price Chart Interactive Chart >
CDNA POWR Grades
- CDNA scores best on the Value dimension, with a Value rank ahead of 90.5% of US stocks.
- The strongest trend for CDNA is in Growth, which has been heading down over the past 177 days.
- CDNA's current lowest rank is in the Growth metric (where it is better than 4.43% of US stocks).
CDNA Stock Summary
- The price/operating cash flow metric for CAREDX INC is higher than 99.86% of stocks in our set with a positive cash flow.
- The ratio of debt to operating expenses for CAREDX INC is higher than it is for about just 15.26% of US stocks.
- With a year-over-year growth in debt of 90.41%, CAREDX INC's debt growth rate surpasses 88.88% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to CAREDX INC are HLIT, KTOS, GTLB, SVVC, and LTRX.
- CDNA's SEC filings can be seen here. And to visit CAREDX INC's official web site, go to www.caredx.com.
CDNA Valuation Summary
- CDNA's EV/EBIT ratio is -3.9; this is 133.62% lower than that of the median Healthcare stock.
- CDNA's price/sales ratio has moved down 3 over the prior 112 months.
Below are key valuation metrics over time for CDNA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CDNA | 2023-09-22 | 1.3 | 1.0 | -4.9 | -3.9 |
| CDNA | 2023-09-21 | 1.4 | 1.0 | -5.0 | -3.9 |
| CDNA | 2023-09-20 | 1.4 | 1.0 | -5.1 | -4.0 |
| CDNA | 2023-09-19 | 1.4 | 1.1 | -5.2 | -4.1 |
| CDNA | 2023-09-18 | 1.4 | 1.1 | -5.1 | -4.0 |
| CDNA | 2023-09-15 | 1.4 | 1.1 | -5.1 | -4.0 |
CDNA Growth Metrics
- The 4 year price growth rate now stands at 2271.96%.
- The 4 year net income to common stockholders growth rate now stands at 42.57%.
- Its 3 year revenue growth rate is now at 248.5%.
The table below shows CDNA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 318.629 | -28.258 | -74.435 |
| 2022-06-30 | 314.859 | -20.797 | -69.393 |
| 2022-03-31 | 308.413 | -7.132 | -49.623 |
| 2021-12-31 | 296.397 | -19.294 | -30.662 |
| 2021-09-30 | 275.821 | -16.279 | -18.026 |
| 2021-06-30 | 253.601 | -11.454 | -8.947 |
CDNA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CDNA has a Quality Grade of C, ranking ahead of 63.01% of graded US stocks.
- CDNA's asset turnover comes in at 0.543 -- ranking 49th of 81 Healthcare stocks.
- MGLN, OPGN, and LH are the stocks whose asset turnover ratios are most correlated with CDNA.
The table below shows CDNA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.543 | 0.676 | -0.174 |
| 2021-06-30 | 0.557 | 0.680 | -0.105 |
| 2021-03-31 | 0.550 | 0.673 | -0.201 |
| 2020-12-31 | 0.628 | 0.672 | -0.382 |
| 2020-09-30 | 0.673 | 0.664 | -0.802 |
| 2020-06-30 | 0.751 | 0.655 | -1.009 |
CDNA Price Target
For more insight on analysts targets of CDNA, see our CDNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $107.33 | Average Broker Recommendation | 1.36 (Strong Buy) |
CareDx, Inc. (CDNA) Company Bio
CareDx, Inc. focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is based in Brisbane, California.
Latest CDNA News From Around the Web
Below are the latest news stories about CAREDX INC that investors may wish to consider to help them evaluate CDNA as an investment opportunity.
CareDx To Present at the 2023 Cantor Global Healthcare ConferenceBRISBANE, Calif., September 19, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the 2023 Cantor Global Healthcare Conference. |
CareDx Advances Global Transplant Patient Care at ESOT Congress 2023BRISBANE, Calif., September 14, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece. |
CareDx To Present at the H.C. Wainwright 25th Annual Global Investment ConferenceBRISBANE, Calif., August 31, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference. |
CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient CareBRISBANE, Calif., August 17, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its second annual digital health user conference, the Management Expert Exchange in Transplantation (MEET) Conference, taking place August 27-29 in Dallas, Texas. |
Redfin upgraded, CSSE downgraded: Wall Street's top analyst callsRedfin upgraded, CSSE downgraded: Wall Street's top analyst calls |
CDNA Price Returns
| 1-mo | -24.81% |
| 3-mo | -17.65% |
| 6-mo | -19.91% |
| 1-year | -58.87% |
| 3-year | -81.55% |
| 5-year | -74.95% |
| YTD | -38.65% |
| 2022 | -74.91% |
| 2021 | -37.23% |
| 2020 | 235.88% |
| 2019 | -14.20% |
| 2018 | 242.51% |
Continue Researching CDNA
Want to see what other sources are saying about CareDx Inc's financials and stock price? Try the links below:CareDx Inc (CDNA) Stock Price | Nasdaq
CareDx Inc (CDNA) Stock Quote, History and News - Yahoo Finance
CareDx Inc (CDNA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...